PAX-8 Rabbit Polyclonal Antibody
Specialties: Anatomic Pathology
PAX-8 is a transcription factor expressed during embryonic development of Müllerian organs, kidney, and thyroid, with continued expression in some epithelial cell types of these mature tissues.1 PAX-8 is a useful marker for neoplasms of gynecologic,2,5,7,10 renal, 3- 9 and thyroid origin.1,4,5,7
This antibody targets the N-terminus of the PAX-8 molecule. This section of the protein is shared with other PAX proteins such as PAX-5 and PAX-6; and thus, some cross-reactivity with these proteins may be observed as evidenced by labeling of selected lymphocytes, and neuroendocrine cells. 7
- Nonaka, Daisuke et al. "Diagnostic utility of thyroid transcription factors Pax8 and TTF-2 (FoxE1) in thyroid epithelial neoplasms." Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc vol. 21,2 (2008): 192-200.
- Nonaka, Daisuke et al. "Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas." The American journal of surgical pathology vol. 32,10 (2008): 1566-71.
- Tong, Guo-Xia et al. "Expression of PAX8 in normal and neoplastic renal tissues: an immunohistochemical study." Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc vol. 22,9 (2009): 1218-27.
- Ozcan, Ayhan et al. "PAX 8 expression in non-neoplastic tissues, primary tumors, and metastatic tumors: a comprehensive immunohistochemical study." Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc vol. 24,6 (2011): 751-64.
- Laury, Anna R et al. "A comprehensive analysis of PAX8 expression in human epithelial tumors." The American journal of surgical pathology vol. 35,6 (2011): 816-26.
- Sangoi, Ankur R et al. "Immunohistochemical distinction of primary adrenal cortical lesions from metastatic clear cell renal cell carcinoma: a study of 248 cases." The American journal of surgical pathology vol. 35,5 (2011): 678-86.
- Ordóñez, Nelson G. "Value of PAX 8 immunostaining in tumor diagnosis: a review and update." Advances in anatomic pathology vol. 19,3 (2012): 140-51.
- Mentrikoski, Mark J et al. "Immunohistochemical distinction of renal cell carcinoma from other carcinomas with clear-cell histomorphology: utility of CD10 and CA-125 in addition to PAX-2, PAX-8, RCCma, and adipophilin." Applied immunohistochemistry & molecular morphology : AIMM vol. 22,9 (2014): 635-41.
- Barr, Meaghan L et al. "PAX-8 expression in renal tumours and distant sites: a useful marker of primary and metastatic renal cell carcinoma?." Journal of clinical pathology vol. 68,1 (2015): 12-7.
- Espinosa, Inigo et al. "Simultaneous carcinomas of the breast and ovary: utility of Pax-8, WT-1, and GATA3 for distinguishing independent primary tumors from metastases." International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists vol. 34,3 (2015): 257-65.
Specifications
- Reactivity: paraffin
- Control: Non-mucinous ovarian carcinoma (Nuclear); Thyroid carcinoma (Nuclear); Renal cell carcinoma (Nuclear)
- Dilution Range: 1:25-1:100 *
Package Inserts
IFU
- IVD Rev. 4.0 (CMC36311040)
Have a different keycode?
Click Here
Learn how to obtain your SDS
Ordering Information
For in vitro diagnostic (IVD) use in USA
| 0.1 mL concentrate | 363A-14 |
| 0.5 mL concentrate | 363A-15 |
| 1.0 mL predilute ready-to-use | 363A-17 |
| 7.0 mL predilute ready-to-use | 363A-18 |
For in vitro diagnostic (IVD) use in Canada
| 0.1 mL concentrate | 363A-14 |
| 0.5 mL concentrate | 363A-15 |
| 1.0 mL predilute ready-to-use | 363A-17 |
| 7.0 mL predilute ready-to-use | 363A-18 |
For in vitro diagnostic (IVD) use in Europe
| 0.1 mL concentrate | 363A-14 |
| 0.5 mL concentrate | 363A-15 |
| 1.0 mL predilute ready-to-use | 363A-17 |
| 7.0 mL predilute ready-to-use | 363A-18 |
For research use only (RUO) in Japan
| 0.1 mL concentrate (RUO) | 363A-14-RUO |
| 0.5 mL concentrate (RUO) | 363A-15-RUO |
| 1.0 mL predilute ready-to-use (RUO) | 363A-17-RUO |
| 7.0 mL predilute ready-to-use (RUO) | 363A-18-RUO |
To request information on this product in additional countries, please click the button below.
